Post-Exposure Prophylaxis for Influenza A

Introduction to Prophylaxis

• The American Academy of Pediatrics recommends oseltamivir 75 mg once daily for 7-10 days after last known exposure for post-exposure prophylaxis of influenza A, initiated as soon as possible and ideally within 48 hours of exposure 1, 2
• The Infectious Diseases Society of America recommends starting oseltamivir prophylaxis as soon as possible after exposure is identified, ideally no later than 48 hours after exposure 1, 2

Timing and Initiation

• The Centers for Disease Control and Prevention recommend that oseltamivir prophylaxis should not be initiated if more than 48 hours has elapsed since exposure; instead, educate patients to start full-dose treatment immediately if symptoms develop 1, 2

Standard Dosing Regimens

• The American Academy of Pediatrics recommends oseltamivir 75 mg once daily for 7-10 days after last known exposure for adults and adolescents (≥13 years) 3, 4, 1, 2
• For pediatric patients (1-12 years), the American Academy of Pediatrics recommends weight-based dosing, once daily for 10 days 3, 4
• For infants (3-11 months), the American Academy of Pediatrics recommends 3 mg/kg once daily for 3-8 months and 3.5 mg/kg once daily for 9-11 months 3, 4

Alternative Agent: Zanamivir

• The Infectious Diseases Society of America recommends zanamivir 10 mg (two 5-mg inhalations) once daily for 7-10 days as an alternative for patients ≥5 years 5, 6, 4
• The World Health Organization recommends zanamivir as the preferred agent for high-risk exposure groups when available, particularly for healthcare workers exposed to oseltamivir-treated H5N1 patients due to potential oseltamivir resistance 6

Risk-Stratified Approach

• The Centers for Disease Control and Prevention recommend a risk-stratified approach for post-exposure prophylaxis, with strong recommendations for high-risk exposure groups, such as household or close family contacts of confirmed influenza patients 6, 7, 1
• The Infectious Diseases Society of America recommends prophylaxis for high-risk individuals, including severely immunocompromised persons for whom vaccination is contraindicated or expected to have low effectiveness 1, 2

Special Populations

• The American College of Obstetricians and Gynecologists recommends prophylaxis for pregnant women in high-risk and moderate-risk exposure groups 6
• The Infectious Diseases Society of America recommends considering prophylaxis for unvaccinated household contacts of persons at very high risk of complications 1, 2

Important Considerations and Monitoring

• The Centers for Disease Control and Prevention recommend testing for influenza and switching to treatment dosing (75 mg twice daily) if symptoms develop during prophylaxis, preferably using an antiviral with a different resistance profile 1, 2
• The American Academy of Pediatrics recommends that prophylaxis does not interfere with antibody response to influenza vaccine 8
• The Infectious Diseases Society of America recommends that prophylaxis is not a substitute for annual influenza vaccination, which remains the primary prevention strategy 3

Concurrent Flu Vaccination and Tamiflu Post-Exposure Prophylaxis

Key Compatibility Points

• The American Academy of Pediatrics states that oseltamivir use is not a contraindication to vaccination with inactivated influenza vaccine (IIV), and prophylaxis does not interfere with antibody response to the vaccine, allowing for simultaneous use in high-risk scenarios 9
• Guidelines recommend the combination of flu vaccination and oseltamivir for children at high risk during the 2 weeks after influenza vaccination, before optimal immunity is achieved, with the American Academy of Pediatrics supporting this approach 10, 11, 12

Clinical Scenarios Where Both Are Recommended

• The American Academy of Pediatrics recommends concurrent use of flu vaccination and oseltamivir for high-risk individuals who received influenza vaccine in the past 2 weeks, as optimal immunity may not yet be achieved 12
• The American Academy of Pediatrics also recommends concurrent use for immunocompromised patients as a supplement to vaccination, including those who are immunocompromised and may not respond with sufficient protective immune responses after vaccination 10, 13
• For children at high risk when circulating strains of influenza virus in the community are not well matched with seasonal vaccine strains, the American Academy of Pediatrics recommends the combination of flu vaccination and oseltamivir 12, 14

Important Caveat with Live Attenuated Vaccine

• While oseltamivir does not interfere with IIV, LAIV effectiveness will be decreased in children receiving oseltamivir, so timing considerations are needed for the live vaccine formulation, according to the American Academy of Pediatrics 9
• The impact of inhaled zanamivir on the effectiveness of LAIV is unknown, as no data are available, as stated by the American Academy of Pediatrics 9

Post-Exposure Prophylaxis Dosing

• For adults and adolescents ≥13 years after exposure, the American Academy of Pediatrics recommends oseltamivir 75 mg once daily for 10 days following close contact with an infected individual 11

Critical Clinical Pearls

• The American Academy of Pediatrics emphasizes that oseltamivir prophylaxis is not a substitute for annual influenza vaccination, which remains the primary means of influenza prevention, and patients should be informed that risk of influenza is lowered but not eliminated while taking medication 9

Oseltamivir Post‑Exposure Prophylaxis: Efficacy and Interaction with Influenza Vaccines

Duration of Protective Effect

Relationship to Influenza Vaccination

Oseltamivir Prophylaxis for Adults

Dosing and Timing

• The CDC recommends a prophylactic regimen of 75 mg oseltamivir taken orally once daily for 10 days, initiated as soon as possible and preferably within 48 hours after confirmed influenza exposure. 16
• Initiation of prophylaxis should occur promptly after exposure, with the optimal window being within 48 hours to maximize preventive benefit. 17

Clinical Efficacy

• During periods of community influenza activity, oseltamivir prophylaxis reduces the risk of laboratory‑confirmed influenza by approximately 74 %–82 % in otherwise healthy adults. 18
• In household‑contact studies where prophylaxis is started within 48 hours of exposure, protective efficacy ranges from 58 % to 84 % for preventing laboratory‑confirmed infection. 18

Renal Dosing Adjustments

• For adults with a creatinine clearance of 10–30 mL/min, the prophylactic dose should be reduced to 75 mg every other day. [16][19]
• No dose modification is required solely on the basis of age for patients aged 65 years or older; standard dosing applies. [16][19]

Vaccination Considerations

• Oseltamivir prophylaxis does not replace annual influenza vaccination; vaccination remains the primary strategy for influenza prevention. 18

Special Populations Warranting Prophylaxis

• Severely immunocompromised adults (e.g., organ‑transplant recipients) may continue oseltamivir prophylaxis for up to 12 weeks during community outbreaks. 19
• Unvaccinated healthcare workers who have frequent contact with high‑risk patients during an outbreak should receive prophylaxis. [18][20]
• Adults who are at high risk for complications and are within two weeks of receiving influenza vaccination—before optimal immunity has developed—should be considered for prophylaxis. 18